This Week in Psychedelics

This week: a new study suggests ketamine may be an effective treatment to sustain abstinence from alcohol

January 14, 2022

This Week...

The American Journal of Psychiatry published the results of a ketamine study that suggests ketamine may be an effective treatment to sustain abstinence from alcohol. Check it out:

On Wednesday, a Missouri lawmaker filed a bill to give residents with serious illnesses legal access to a range of psychedelic drugs like psilocybin, ibogaine and LSD through an expanded version of the state’s existing right-to-try law.  Here’s more:

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) announced this week that it’s launching a special support and supply program to provide products and services to physicians, clinics, and hospitals in Canada that are looking to treat patients through psychedelic-assisted psychotherapy.  This news comes after Health Canada announced an amendment to federal regulations, granting practitioners and pharmacists the ability to request and prescribe psilocybin and MDMA for treatment-resistant patients. You can read more about that here:

Did You Know?

Did you know that MDMA was first synthesized by German chemists in 1912?  It was originally known as Methylsafrylaminc, and it was intended as a parent compound to synthesize medications that control bleeding.  

Today, more than a hundred years later, researchers have discovered following a phase 3 clinical trial that MDMA-assisted therapy is an effective treatment for patients with severe, chronic post-traumatic stress disorder (PTSD).